Agilent to acquire Biocare Medical for $950M, supercharging cancer diagnostics portfolio

The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth

BPL Medical Tech acquires South Korea’s Yozma BMtech

Launches advanced bone density systems in India & Dubai

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases

Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million

Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

Siegfried delivers strong 2025 performance, bolsters US expansion

Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates